{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:23:25Z","timestamp":1786987405132,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-025-02138-0","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:27:49Z","timestamp":1764588469000},"page":"582-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["[18F]FDG PET\/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?"],"prefix":"10.1007","volume":"131","author":[{"given":"Riccardo","family":"Gerosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Gelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Benvenuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Canzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Tinterri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Antunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-1933","authenticated-orcid":false,"given":"Rita","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2138_CR1","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.breast.2021.12.019","volume":"62","author":"IT Rubio","year":"2022","unstructured":"Rubio IT, Sobrido C (2022) Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning. Breast 62:S17-24","journal-title":"Breast"},{"issue":"2","key":"2138_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ et al (2024) Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35(2):159\u2013182","journal-title":"Ann Oncol"},{"issue":"9938","key":"2138_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164\u2013172","journal-title":"Lancet"},{"key":"2138_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103280","volume":"160","author":"R Torrisi","year":"2021","unstructured":"Torrisi R, Marrazzo E, Agostinetto E, De Sanctis R, Losurdo A, Masci G et al (2021) Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: when, why and what? Crit Rev Oncol Hematol 160:103280","journal-title":"Crit Rev Oncol Hematol"},{"key":"2138_CR5","unstructured":"NCCN (2025) Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer Version 4. In: NCCN.org"},{"issue":"1","key":"2138_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00259-024-06882-9","volume":"52","author":"M Kirienko","year":"2024","unstructured":"Kirienko M, Gelardi F, Fiz F, Bauckneht M, Ninatti G, Pini C et al (2024) Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication. Eur J Nucl Med Mol Imaging 52(1):208\u2013224","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2138_CR7","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1097\/RLU.0000000000001191","volume":"41","author":"AM Garc\u00eda Vicente","year":"2016","unstructured":"Garc\u00eda Vicente AM, Amo-Salas M, Relea Calatayud F, Mu\u00f1oz S\u00e1nchez MDM, Pena Pardo FJ, Jim\u00e9nez Londo\u00f1o GA et al (2016) Prognostic role of early and end-of-neoadjuvant treatment 18F-FDG PET\/CT in patients with breast cancer. Clin Nucl Med 41(7):e313\u2013e322","journal-title":"Clin Nucl Med"},{"issue":"9","key":"2138_CR8","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00259-024-06694-x","volume":"51","author":"D Groheux","year":"2024","unstructured":"Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM et al (2024) Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: differences and agreements with European and American guidelines. Eur J Nucl Med Mol Imaging 51(9):2701\u20132705","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2138_CR9","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA et al (2024) Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging 51(9):2706\u20132732","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"2138_CR10","doi-asserted-by":"publisher","first-page":"34S","DOI":"10.2967\/jnumed.115.157875","volume":"57","author":"S Avril","year":"2016","unstructured":"Avril S, Muzic RF, Plecha D, Traughber BJ, Vinayak S, Avril N (2016) 18F-FDG PET\/CT for monitoring of treatment response in breast cancer. J Nucl Med 57(Suppl 1):34S-39S","journal-title":"J Nucl Med"},{"issue":"4","key":"2138_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/cncr.24820","volume":"116","author":"AA Martoni","year":"2010","unstructured":"Martoni AA, Zamagni C, Quercia S, Rosati M, Cacciari N, Bernardi A et al (2010) Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer 116(4):805\u2013813","journal-title":"Cancer"},{"issue":"8","key":"2138_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1634\/theoncologist.2015-0353","volume":"21","author":"S Sheikhbahaei","year":"2016","unstructured":"Sheikhbahaei S, Trahan TJ, Xiao J, Taghipour M, Mena E, Connolly RM et al (2016) FDG-PET\/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies. Oncologist 21(8):931\u2013939","journal-title":"Oncologist"},{"key":"2138_CR13","first-page":"1","volume":"2016","author":"Q Liu","year":"2016","unstructured":"Liu Q, Wang C, Li P, Liu J, Huang G, Song S (2016) The role of 18 F-FDG PET\/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis. BioMed Res Int 2016:1\u201310","journal-title":"BioMed Res Int"},{"issue":"1","key":"2138_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00330-011-2236-x","volume":"22","author":"SH Park","year":"2012","unstructured":"Park SH, Moon WK, Cho N, Chang JM, Im SA, Park IA et al (2012) Comparison of diffusion-weighted MR imaging and FDG PET\/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 22(1):18\u201325","journal-title":"Eur Radiol"},{"issue":"9586","key":"2138_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(07)61232-X","volume":"370","author":"CK Kuhl","year":"2007","unstructured":"Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R et al (2007) MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 370(9586):485\u2013492","journal-title":"Lancet"},{"issue":"4","key":"2138_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0284185113498720","volume":"55","author":"T Kim","year":"2014","unstructured":"Kim T, Kang DK, An YS, Yim H, Jung YS, Kim KS et al (2014) Utility of MRI and PET\/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. Acta Radiol 55(4):399\u2013408","journal-title":"Acta Radiol"},{"issue":"1","key":"2138_CR17","first-page":"3","volume":"4","author":"S Kiyoto","year":"2016","unstructured":"Kiyoto S, Sugawara Y, Hosokawa K, Nishimura R, Yamashita N, Ohsumi S et al (2016) Predictive Ability of 18F-fluorodeoxyglucose Positron Emission Tomography\/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients. Asia Ocean J Nucl Med Biol 4(1):3\u201311","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"5","key":"2138_CR18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000524446","volume":"17","author":"S Goktas Aydin","year":"2022","unstructured":"Goktas Aydin S, Bilici A, Olmez OF, Oven BB, Acikgoz O, Cakir T et al (2022) The role of 18F-FDG PET\/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer. Breast Care 17(5):470\u2013479","journal-title":"Breast Care"},{"issue":"1","key":"2138_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.bjc.6605427","volume":"102","author":"J Dose-Schwarz","year":"2010","unstructured":"Dose-Schwarz J, Tiling R, Avril-Sassen S, Mahner S, Lebeau A, Weber C et al (2010) Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer 102(1):35\u201341","journal-title":"Br J Cancer"},{"issue":"3","key":"2138_CR20","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1186\/bcr2591","volume":"12","author":"ME Schneider-Kolsky","year":"2010","unstructured":"Schneider-Kolsky ME, Hart S, Fox J, Midolo P, Stuckey J, Hofman M et al (2010) The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 12(3):R37","journal-title":"Breast Cancer Res"},{"issue":"10","key":"2138_CR21","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1093\/annonc\/mds071","volume":"23","author":"O Humbert","year":"2012","unstructured":"Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A et al (2012) Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 23(10):2572\u20132577","journal-title":"Ann Oncol"},{"issue":"2","key":"2138_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2967\/jnumed.111.094045","volume":"53","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A et al (2012) Triple-negative breast cancer: early assessment with 18 F-FDG PET\/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 53(2):249\u2013254","journal-title":"J Nucl Med"},{"key":"2138_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.008","author":"K Van Baelen","year":"2025","unstructured":"Van Baelen K, Sawyer E, Van Cauwenberge J, Aftimos P, Covington MF, Maetens M et al (2025) Clinical challenges and proposed solutions for patients with invasive lobular breast cancer. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.008","journal-title":"Ann Oncol"},{"issue":"2","key":"2138_CR24","first-page":"153","volume":"51","author":"N Yildirim","year":"2019","unstructured":"Yildirim N, Simsek M, Aldemir MN, Bilici M, Tekin SB (2019) Relationship between 18-FDG-PET\/CT and clinicopathological features and pathological responses in patients with locally advanced breast cancers. Eur J Med 51(2):153\u2013158","journal-title":"Eur J Med"},{"issue":"2","key":"2138_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-011-1780-z","volume":"131","author":"Y Wang","year":"2012","unstructured":"Wang Y, Zhang C, Liu J, Huang G (2012) Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 131(2):357\u2013369","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2138_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00259-007-0459-5","volume":"34","author":"A Berriolo-Riedinger","year":"2007","unstructured":"Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L et al (2007) [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34(12):1915\u20131924","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"34","key":"2138_CR27","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1200\/JCO.2006.05.7406","volume":"24","author":"C Rousseau","year":"2006","unstructured":"Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18 F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24(34):5366\u20135372","journal-title":"J Clin Oncol"},{"issue":"4","key":"2138_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1200\/JCO.2008.17.2650","volume":"27","author":"J Schwarz-Dose","year":"2009","unstructured":"Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18 F]fluorodeoxyglucose. J Clin Oncol 27(4):535\u2013541","journal-title":"J Clin Oncol"},{"issue":"1","key":"2138_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1258\/ar.2010.100142","volume":"52","author":"JS Park","year":"2011","unstructured":"Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK (2011) The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. Acta Radiol 52(1):21\u201328","journal-title":"Acta Radiol"},{"key":"2138_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jss.2022.04.063","volume":"278","author":"H Baysal","year":"2022","unstructured":"Baysal H, Serdaroglu AY, Ozemir IA, Baysal B, Gungor S, Erol CI et al (2022) Comparison of magnetic resonance imaging with positron emission tomography\/computed tomography in the evaluation of response to neoadjuvant therapy of breast cancer. J Surg Res 278:223\u2013232","journal-title":"J Surg Res"},{"key":"2138_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104432","volume":"81","author":"MA Hennessy","year":"2025","unstructured":"Hennessy MA, Cimino-Mathews A, Carter JM, Kachergus JM, Ma Y, Leal JP et al (2025) A composite 18F-FDG PET\/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). Breast 81:104432","journal-title":"Breast"},{"issue":"10437","key":"2138_CR32","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","volume":"403","author":"JM P\u00e9rez-Garc\u00eda","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda JM, Cort\u00e9s J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B et al (2024) 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 403(10437):1649\u20131659","journal-title":"Lancet"},{"issue":"16_suppl","key":"2138_CR33","doi-asserted-by":"publisher","first-page":"TPS624","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS624","volume":"42","author":"PD Zavras","year":"2024","unstructured":"Zavras PD, Chen R, Qi H, Solnes L, Canzoniero JV, Denbow R et al (2024) A pilot study of early PET and biomarker dynamics in patients with stage 2 and 3 triple negative breast cancer treated with neoadjuvant response-adapted chemotherapy with pembrolizumab (NeoADAPT). J Clin Oncol 42(16_suppl):TPS624\u2013TPS624","journal-title":"J Clin Oncol"},{"issue":"2","key":"2138_CR34","first-page":"183","volume":"80","author":"K Kitajima","year":"2018","unstructured":"Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K (2018) Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET\/CT-RECIST 1.1 vs. PERCIST 1.0. Nagoya J Med Sci 80(2):183\u2013197","journal-title":"Nagoya J Med Sci"},{"issue":"10","key":"2138_CR35","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00259-018-4008-1","volume":"45","author":"K Kitajima","year":"2018","unstructured":"Kitajima K, Nakatani K, Yamaguchi K, Nakajo M, Tani A, Ishibashi M et al (2018) Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST \u2013 multicenter study in Japan. Eur J Nucl Med Mol Imaging 45(10):1661\u20131671","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2138_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13058-020-01350-2","volume":"22","author":"S Han","year":"2020","unstructured":"Han S, Choi JY (2020) Prognostic value of 18F-FDG PET and PET\/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 22(1):119","journal-title":"Breast Cancer Res"},{"issue":"9","key":"2138_CR37","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2967\/jnumed.115.158287","volume":"56","author":"L Champion","year":"2015","unstructured":"Champion L, Lerebours F, Alberini JL, Fourme E, Gontier E, Bertrand F et al (2015) 18f-fdg PET\/CT to predict response to neoadjuvant chemotherapy and prognosis in inflammatory breast cancer. J Nucl Med 56(9):1315\u20131321","journal-title":"J Nucl Med"},{"key":"2138_CR38","doi-asserted-by":"publisher","first-page":"205520762412888","DOI":"10.1177\/20552076241288821","volume":"10","author":"F Jacobs","year":"2024","unstructured":"Jacobs F, Damico S, Zazzetti E, Gaudio M, Benvenuti C, Saltalamacchia G et al (2024) Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems. Digit Health 10:20552076241288820","journal-title":"Digit Health"},{"issue":"4","key":"2138_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11547-025-01958-4","volume":"130","author":"L Urso","year":"2025","unstructured":"Urso L, Manco L, Cittanti C, Adamantiadis S, Szilagyi KE, Scribano G et al (2025) 18F-FDG PET\/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Radiol Med 130(4):543\u2013554","journal-title":"Radiol Med"},{"issue":"20","key":"2138_CR40","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/diagnostics14202312","volume":"14","author":"F Gelardi","year":"2024","unstructured":"Gelardi F, Cavinato L, De Sanctis R, Ninatti G, Tiberio P, Rodari M et al (2024) The predictive role of radiomics in breast cancer patients imaged by [18F]FDG PET: preliminary results from a prospective cohort. Diagnostics 14(20):2312","journal-title":"Diagnostics"},{"issue":"3","key":"2138_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.remnie.2024.500002","volume":"43","author":"A Aksu","year":"2024","unstructured":"Aksu A, G\u00fc\u00e7 ZG, K\u00fc\u00e7\u00fcker KA, Alacac\u0131o\u011flu A, Turgut B (2024) Intra and peritumoral PET radiomics analysis to predict the pathological response in breast cancer patients receiving neoadjuvant chemotherapy. Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition) 43(3):500002","journal-title":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"},{"key":"2138_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115519","volume":"224","author":"R Di Micco","year":"2025","unstructured":"Di Micco R, Botteri E, Canevari C, Gallivanone F, Antunovic L, Scifo P et al (2025) [18F]FDG PET\/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial. Eur J Cancer 224:115519","journal-title":"Eur J Cancer"},{"issue":"9","key":"2138_CR43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s12032-025-02982-0","volume":"42","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Low J, Huang C, Yue Y, Njeh C, Oderinde O (2025) 18F-FDG PET\/CT-based deep radiomic models for enhancing chemotherapy response prediction in breast cancer. Med Oncol 42(9):425","journal-title":"Med Oncol"},{"issue":"7","key":"2138_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071249","volume":"17","author":"D Groheux","year":"2025","unstructured":"Groheux D, Ferrer L, Vargas J, Martineau A, Borgel A, Teixeira L et al (2025) FDG-PET\/CT and multimodal machine learning model prediction of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Cancers (Basel) 17(7):1249","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2138_CR45","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2967\/jnumed.122.265364","volume":"64","author":"A Alhuseinalkhudhur","year":"2023","unstructured":"Alhuseinalkhudhur A, Lindman H, Liss P, Sundin T, Frejd FY, Hartman J et al (2023) Human epidermal growth factor receptor 2\u2013targeting [68 Ga]Ga-ABY-025 PET\/CT predicts early metabolic response in metastatic breast cancer. J Nucl Med 64(9):1364\u20131370","journal-title":"J Nucl Med"},{"issue":"4","key":"2138_CR46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.123.266798","volume":"65","author":"E Sahin","year":"2024","unstructured":"Sahin E, Kus T, Aytekin A, Uzun E, Elboga U, Yilmaz L et al (2024) 68 Ga-FAPI PET\/CT as an alternative to 18 F-FDG PET\/CT in the imaging of invasive lobular breast carcinoma. J Nucl Med 65(4):512\u2013519","journal-title":"J Nucl Med"},{"issue":"16","key":"2138_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165355","volume":"12","author":"M Caracciolo","year":"2023","unstructured":"Caracciolo M, Castello A, Urso L, Borgia F, Marzola MC, Uccelli L et al (2023) Comparison of MRI vs. [18F]FDG PET\/CT for treatment response evaluation of primary breast cancer after neoadjuvant chemotherapy: literature review and future perspectives. J Clin Med 12(16):5355","journal-title":"J Clin Med"},{"issue":"6","key":"2138_CR48","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00259-011-1735-y","volume":"38","author":"C Rousseau","year":"2011","unstructured":"Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C et al (2011) FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging 38(6):1029\u20131036","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2138_CR49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/1471-2407-11-452","volume":"11","author":"B Keam","year":"2011","unstructured":"Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N et al (2011) Early metabolic response using FDG PET\/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 11(1):452","journal-title":"BMC Cancer"},{"issue":"2","key":"2138_CR50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-011-1832-4","volume":"131","author":"H Kolesnikov-Gauthier","year":"2012","unstructured":"Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC, Vennin P, Servent V, Fournier C et al (2012) Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG\u2013PET after the first course. Breast Cancer Res Treat 131(2):517\u2013525","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2138_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10147-011-0287-2","volume":"17","author":"S Ueda","year":"2012","unstructured":"Ueda S, Saeki T, Shigekawa T, Omata J, Moriya T, Yamamoto J et al (2012) 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol 17(3):276\u2013282","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"2138_CR52","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2967\/jnumed.112.119271","volume":"54","author":"G Gebhart","year":"2013","unstructured":"Gebhart G, G\u00e1mez C, Holmes E, Robles J, Garcia C, Cort\u00e9s M et al (2013) 18 F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med 54(11):1862\u20131868","journal-title":"J Nucl Med"},{"issue":"11","key":"2138_CR53","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/cncr.28020","volume":"119","author":"D Groheux","year":"2013","unstructured":"Groheux D, Hatt M, Hindi\u00e9 E, Giacchetti S, de Cremoux P, Lehmann-Che J et al (2013) Estrogen receptor-positive\/human epidermal growth factor receptor 2-negative breast tumors. Cancer 119(11):1960\u20131968","journal-title":"Cancer"},{"issue":"3","key":"2138_CR54","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2967\/jnumed.112.108837","volume":"54","author":"M Hatt","year":"2013","unstructured":"Hatt M, Groheux D, Martineau A, Espi\u00e9 M, Hindi\u00e9 E, Giacchetti S et al (2013) Comparison between 18 F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54(3):341\u2013349","journal-title":"J Nucl Med"},{"issue":"2","key":"2138_CR55","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12282-011-0323-0","volume":"20","author":"B Keam","year":"2013","unstructured":"Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N et al (2013) Predictive value of FDG PET\/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. Breast Cancer 20(2):167\u2013173","journal-title":"Breast Cancer"},{"issue":"5","key":"2138_CR56","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","volume":"22","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJTFD, Vincent AD et al (2013) FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast 22(5):691\u2013697","journal-title":"Breast"},{"issue":"7","key":"2138_CR57","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1245\/s10434-013-2902-0","volume":"20","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Vald\u00e9s Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KGA et al (2013) Early Assessment of Axillary Response with 18F-FDG PET\/CT during Neoadjuvant Chemotherapy in Stage II\u2013III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol 20(7):2227\u20132235","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"2138_CR58","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(14)70475-9","volume":"15","author":"B Coudert","year":"2014","unstructured":"Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T et al (2014) Use of [18f]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol 15(13):1493\u20131502","journal-title":"Lancet Oncol"},{"issue":"8","key":"2138_CR59","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00259-014-2739-1","volume":"41","author":"O Humbert","year":"2014","unstructured":"Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B et al (2014) HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41(8):1525\u20131533","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2138_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00259-013-2515-7","volume":"41","author":"BB Koolen","year":"2014","unstructured":"Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJTFD, Vincent AD et al (2014) Sequential 18F-FDG PET\/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41(1):32\u201340","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"30","key":"2138_CR61","doi-asserted-by":"publisher","first-page":"29388","DOI":"10.18632\/oncotarget.5001","volume":"6","author":"J Cheng","year":"2015","unstructured":"Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G et al (2015) 18F-fluorodeoxyglucose (FDG) PET\/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Oncotarget 6(30):29388\u201329395","journal-title":"Oncotarget"},{"issue":"1","key":"2138_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2967\/jnumed.114.144741","volume":"56","author":"RM Connolly","year":"2015","unstructured":"Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK et al (2015) TBCRC 008: early change in 18 F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2\u2013negative primary operable breast cancer. J Nucl Med 56(1):31\u201337","journal-title":"J Nucl Med"},{"issue":"24","key":"2138_CR63","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1158\/1078-0432.CCR-15-0384","volume":"21","author":"O Humbert","year":"2015","unstructured":"Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V et al (2015) Identification of biomarkers including 18FDG-PET\/CT for early prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer. Clin Cancer Res 21(24):5460\u20135468","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2138_CR64","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.115.163907","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Biard L, Giacchetti S, Teixeira L, Hindi\u00e9 E, Cuvier C et al (2016) 18 f-FDG PET\/CT for the early evaluation of response to neoadjuvant treatment in triple-negative breast cancer: influence of the chemotherapy regimen. J Nucl Med 57(4):536\u2013543","journal-title":"J Nucl Med"},{"issue":"1","key":"2138_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40644-017-0117-5","volume":"17","author":"MS van Ramshorst","year":"2017","unstructured":"van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J et al (2017) Additional value of 18F-FDG PET\/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer. Cancer Imaging 17(1):15","journal-title":"Cancer Imaging"},{"issue":"23","key":"2138_CR66","doi-asserted-by":"publisher","first-page":"16343","DOI":"10.18632\/oncotarget.24674","volume":"9","author":"P de Cremoux","year":"2018","unstructured":"de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J et al (2018) 18FDG-PET\/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. Oncotarget 9(23):16343\u201316353","journal-title":"Oncotarget"},{"issue":"8","key":"2138_CR67","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00259-018-3998-z","volume":"45","author":"D Groheux","year":"2018","unstructured":"Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B et al (2018) Tumor metabolism assessed by FDG-PET\/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. Eur J Nucl Med Mol Imaging 45(8):1279\u20131288","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"2138_CR68","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1200\/JCO.21.00280","volume":"39","author":"RM Connolly","year":"2021","unstructured":"Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K et al (2021) Updated results of TBCRC026: phase II trial correlating standardized uptake value with pathological complete response to Pertuzumab and Trastuzumab in breast cancer. J Clin Oncol 39(20):2247\u20132256","journal-title":"J Clin Oncol"},{"issue":"5","key":"2138_CR69","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2967\/jnumed.123.266384","volume":"65","author":"G Gebhart","year":"2024","unstructured":"Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A et al (2024) Optimal [18 F]FDG PET\/CT cutoff for pathologic complete response in HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab and pertuzumab in the PHERgain trial. J Nucl Med 65(5):708\u2013713","journal-title":"J Nucl Med"},{"issue":"1","key":"2138_CR70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40644-025-00914-9","volume":"25","author":"L Guichard","year":"2025","unstructured":"Guichard L, Nunes P, Jankowski C, Bertaut A, Michel E, Ladoire S et al (2025) Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes. Cancer Imaging 25(1):110","journal-title":"Cancer Imaging"},{"issue":"10","key":"2138_CR71","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1245\/s10434-013-3118-z","volume":"20","author":"TJ Hieken","year":"2013","unstructured":"Hieken TJ, Boughey JC, Jones KN, Shah SS, Glazebrook KN (2013) Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol 20(10):3199\u20133204","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2138_CR72","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jjco\/hyv215","volume":"46","author":"A Amioka","year":"2016","unstructured":"Amioka A, Masumoto N, Gouda N, Kajitani K, Shigematsu H, Emi A et al (2016) Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy. Jpn J Clin Oncol 46(4):303\u2013309","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2138_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.clbc.2017.09.006","volume":"18","author":"E Akimoto","year":"2018","unstructured":"Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M et al (2018) Role of 18F-PET\/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer 18(1):45\u201352","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"2138_CR74","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1186\/s12885-020-07505-w","volume":"20","author":"IH Lee","year":"2020","unstructured":"Lee IH, Lee SJ, Lee J, Jung JH, Park HY, Jeong SY et al (2020) Utility of 18F-FDG PET\/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer 20(1):1106","journal-title":"BMC Cancer"},{"issue":"3","key":"2138_CR75","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/wjs.12454","volume":"49","author":"LWY Ma","year":"2025","unstructured":"Ma LWY, Cheung PSY, Ho CL, Wong YH, Luk WP, Fung LH (2025) Correlation on metabolic complete response on positron emission tomography and pathological complete response in patients with breast cancer after neoadjuvant chemotherapy. World J Surg 49(3):570\u2013575","journal-title":"World J Surg"},{"issue":"13","key":"2138_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132133","volume":"17","author":"F Gelardi","year":"2025","unstructured":"Gelardi F, Tiberio P, Torrisi R, Zanca R, Rodari M, Zambelli A et al (2025) Using [18F]FDG PET\/CT to identify optimal responders to neoadjuvant therapy in breast cancer\u2014results from a prospective patient cohort. Cancers (Basel) 17(13):2133","journal-title":"Cancers (Basel)"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02138-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-02138-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-02138-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:03:09Z","timestamp":1776852189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-02138-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2138"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-02138-0","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Declarations of interest: none related to the content of the manuscript or to the subject matter. Outside the submitted work, the authors declare the following financial interests\/personal relationships: RG: Travel\/meeting grants from Novartis and Daiichi Sankyo. AS: Advisory Board: Bristol-Myers-Squibb (BMS), Servier, Gilead, Pfizer, Eisai, Bayer, Merck Sharp and Dohme (MSD). Consultancy: Arqule, Sanofi, Incyte. Speaker\u2019s Bureau: Takeda, BMS, Roche, Abb-Vie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD (all outside the submitted work). RDS: honoraria for advisory board consultancy from Novartis, Istituto Clinico Gentili, Amgen, EISAI, Lilly, Gilead, and Ipsen (all outside the present work). AZ: honoraria and advisory board consultancy from Novartis, AstraZeneca, Lilly, Pfizer, Daiichi Sankyo, MSD, Roche, Seagen, Exact Sciences, Gilead, Istituto Gentili (all outside the present work).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}